According to research published in Diabetologia, the journal of the European Association for the Study of Diabetes, people who have diabetes at the time they are diagnosed with cancer are more likely to die early than those without diabetes.
The researchers have concluded that patients with both diabetes and cancer constitute a particularly vulnerable group, and efforts are needed to reduce cancer-related mortality among these patients.
The aim of this study was to explore differences in survival among cancer patients with diabetes prior to cancer diagnosis compared with cancer patients without diabetes.
It has also been explored the association between different types of glucose-lowering therapies and survival after cancer diagnosis, as well as to examine how this association varies with duration of diabetes and by time since diagnosis of cancer.
This register-based study included all cancer patients diagnosed in Denmark during 1995-2009. The patients were classified into four groups according to diabetes status at the time of cancer diagnosis: no diabetes, diabetes without medication, diabetes with only oral hypoglycaemic agents or diabetes with insulin treatment.
Since the study is entirely observational, the researchers stress that causality cannot be inferred.
The patients with 2 years of diabetes duration and treated with Insulin at the time of cancer diagnosis have 4 times higher mortality one year after cancer diagnosis. The figure is slightly different between men ( 3.7 ) and women ( 4.4 ), and there is a small increase by time since cancer diagnosis, to a 5 times increased mortality at 5 years since cancer diagnosis.
For people with diabetes using only oral antidiabetic drugs ( for example, Metformin ), the increased risk of death was much lower, at 10% for both men and women one year after cancer diagnosis having had diabetes for two years versus non-diabetics.
After 5 years, this increased risk was 50% for both men and women. For those who were not on any form of diabetes treatment, the increased risk of death was very similar to those for patients on oral antidiabetic drugs.
The results suggest that mortality of cancer patients with pre-existing diabetes is higher relative to non-diabetic patients for all cancers combined and for most individual cancer sites.
In general, the highest mortality was found for insulin-treated patients, suggesting that cancer patients with more intensive diabetes treatment have a larger degree of comorbidity at the time of cancer diagnosis, and hence poorer survival.
Diabetes duration at cancer diagnosis did not influence the prognosis.
Differences in cancer treatment between patients with and without diabetes may contribute to increased cancer-related mortality. Patients with diabetes often have other diabetes-related comorbid conditions, such as ischaemic heart disease, chronic kidney disease and neuropathy, that may influence clinical decisions.
Statistically significant increases in mortality were observed among all three groups of patients with diabetes for all cancers combined, and for colorectal, breast, ovary, cervix and corpus uteri, and bladder cancer.
In addition, patients treated with Insulin had a significant mortality increase for all previously mentioned cancers, as well as for rectum, lung and prostate cancer.
In conclusion, the study has provided strong support for the notion that pre-existing diabetes increases mortality among cancer patients, and that the excess mortality is larger among patients with diabetes treated with oral hypoglycaemic agents or, particularly, Insulin. ( Xagena )
Source: Diabetologia, 2014